UrgentRx

About UrgentRx

UrgentRx, founded in 2010 by serial entrepreneur Jordan Eisenberg, operated in the over-the-counter (OTC) pharmaceutical market, targeting on-the-go consumers. The company's inception was driven by Eisenberg's personal experience with food allergies and the inconvenience of carrying medication, which led to the concept of portable, single-dose medicines. Initially, the product was developed as a portable aspirin for potential heart attack victims, a concept sparked by observing his father's friends carrying aspirin.

The business centered on producing and distributing a line of fast-acting, flavored powdered medications packaged in credit card-sized packets that could be consumed without water. This delivery system was designed to allow the medication to enter the bloodstream more rapidly than traditional pills. The product portfolio expanded from its original critical care aspirin to include remedies for common ailments like headaches, heartburn, allergy attacks, and upset stomachs. UrgentRx's business model focused on retail sales, securing distribution in over 35,000 stores, including major national chains like CVS and Walgreens. A key part of their strategy involved a creative merchandising approach, utilizing previously unused spaces at checkout counters with patent-pending displays, which helped them gain retail presence without directly competing for high-cost shelf space.

Eisenberg, a Vanderbilt University graduate with a background in mathematics and engineering, had a history of inventing and entrepreneurship before UrgentRx, including launching a mobile app and licensing a medical device. He successfully attracted a high-profile board, including the former CEOs of Mucinex and Emergen-C, and notable investors such as Sam Zell and Hilary Swank. The company raised approximately $25 million in cumulative funding by July 2014. In November 2015, UrgentRx, legally known as Breakthrough Products, Inc., was acquired by Synergy CHC Corp., a consumer healthcare company, in a stock and royalty deal.